tbuckley/cabot-search huggingface dataset:
Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis
Authors: David Hodgson, Marc Baguelin, Edwin van Leeuwen, Jasmina Panovska-Griffiths, Mary Ramsay, Richard Pebody, Katherine E Atkins
Journal: The Lancet Public Health (2017)

In 2013 England and Wales began to fund a live attenuated influenza vaccine programme for individuals aged 2-16 years. Mathematical modelling predicts substantial beneficial herd effects for the entire population as a result of reduced influenza transmission. With a decreased influenza-associated disease burden, existing immunisation programmes might be less cost-effective. The aim of this study was to assess the epidemiological effect and cost-effectiveness of the existing elderly and risk group vaccination programme under the new policy of mass paediatric vaccination in England.
Margaret McCartney: Referrals for weight management are a mess
Authors: Margaret McCartney
Journal: BMJ (2017)

“GP referral to weight loss programmes is effective, acceptable, and takes 30 seconds,” said a Lancet press release.1

Paul Aveyard, who led the study, said, “Doctors can be concerned about offending their patients by discussing their weight, but evidence from this trial shows that they should be much less worried. Our study found that a brief, 30 second conversation, followed by help booking the first appointment onto a community weight loss programme, leads to weight loss and is welcomed by patients.”

The study involved 137 general practices in England.2 To …
Expression of the tumor suppressor gene ARHI induces autophagic cell death in ovarian cancer cells
Authors: Robert Z. Luo, Zhen Lu, Shilpi Khare, Yiling Lu, Gordon B. Mills, Yinhua Yu, Robert C. Bast
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

844 

ARHI, a Ras superfamily member, is expressed in normal ovarian epithelial cells, but markedly downregulated or lost in the majority of ovarian cancers. Introduction of this gene, by adenovirus-ARHI infection into cancer cells that lack ARHI expression inhibits cancer cell growth and motility, and triggers caspase-independent apoptosis. The mechanism by which ARHI inhibits ovarian cancer growth is still not clear. In the present study, we explored ARHI induced autophagy using a stable Tet-On SKOv3-ARHI inducible ovarian cancer cell line. Inducing modest expression of ARHI in SKOv3 cells markedly inhibited cancer cell proliferation, triggered G2M cell cycle arrest, and induced cell death. The growth arrest by induction of ARHI was accompanied by several specific features characteristic of autophagy in a time-dependent manner: 1) presence of numerous autophagic vacuoles in the cytoplasm, 2) development of acidic vesicular organelles, and 3) markedly increased expression of autophagosome membrane specific microtubular-associated protein light chain 3 protein (LC3-I and LC3-II). Electron microscopy revealed typical morphology and ultrastructural changes indicative of autophagic cell death. In contrast, only a few percent of cells developed apoptosis at 4 days after induction. Consistent with our previous data that the N-terminal plays an important role in ARHI induced cell growth, the N-terminal deletion (NTD) mutant ARHI produced very modest growth inhibition and a mild autophagic effect. Together, these findings show that a Ras family member and a tumor suppressor gene ARHI induces cell death in ovarian cancer cells through a mechanism of autophagic cell death, a mechanism distinct from apoptosis. Understanding this unique pathway would provide a novel insight on the therapy of ovarian cancers that are chemoresistant on the basis of ineffective apoptosis.
Identification of Minor Histocompatibility Antigens Based on the 1000 Genomes Project for Application in Therapeutic Dendritic Cell Vaccination
Authors: Rimke Oostvogels, Henk M. Lokhorst, Maureen van Elk, Kelly van den Oudenalder, Eric Spierings, Monique C. Minnema, Tuna Mutis, Robbert Spaapen
Journal: Blood (2014)
The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.
Authors: Michael K. Wenger, Robin Foa, Luca Arcaini, Andrej Vranovský, Valentina Ivanova, Van Hazel Guy, Sabira Kurtovic, Soledad Durán, Stephen McKechnie, Daniel Thurley
Journal: Blood (2007)
Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy
Authors: Vladimir I. Vorobyev, Yuri Yu. Lorie, Evgenii' E. Zvonkov, Eduard G. Gemdjian, Aminat U. Magomedova, Anait L. Melikyan, Jana K. Mangasarova, Elena O. Gribanova, Vera A. Zherebtsova, Sergey K. Kravchenko, Valeri G. Savchenko
Journal: Blood (2012)
P1.08-051 VATS Lobectomy Combined with Limited Thoracotomy for Treatment of Superior Sulcus Tumors
Authors: Davide Tosi, Lorenzo Rosso, Alessandro Palleschi, Paolo Mendogni, Ilaria Righi, Matteo Montoli, Claudia Bareggi, Mario Nosotti
Journal: Journal of Thoracic Oncology (2017)
P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice
Authors: Giannis Mountzios, Biagio Ricciuti, Rita Chiari, Marina Baretti, Lorenzo Falcinelli, Diana Giannarelli, Angelo Sidoni, Lucio Crinò, Guido Bellezza, Alberto Rebonato, Piero Ferolla, Luca Toschi, Giulio Metro
Journal: Journal of Thoracic Oncology (2017)
P1.08-052 Comparison Study of Perioperative Outcomes in Robotic, Video-Assisted Thoracic Surgery, and Thoracotomy Approaches for Lung Cancer
Authors: Hiroshige Nakamura, Yuji Taniguchi, Ken Miwa, Kunio Araki, Tomohiro Haruki, Makoto Wakahara, Yohei Yurugi, Yasuaki Kubouchi, Yoshiteru Kidokoro, Takashi Ono
Journal: Journal of Thoracic Oncology (2017)
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
Authors: Yu Huang, Bo Jia, Shiyu Jiang, Shengyu Zhou, Jianliang Yang, Peng Liu, Lin Gui, Xiaohui He, Yan Qin, Yan Sun, Yuankai Shi
Journal: Journal of Hematology & Oncology (2017)

The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were 61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy (IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS (73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result in similarly favorable prognoses.
PUB105 Hybrid-Capture Based Comprehensive Genomic Profiling Detects EGFR Point Mutations in &gt;20% of Patients Missed by Standard of Care Testing
Authors: James Suh, Alexa Schrock, Adrienne Johnson, Doron Lipson, Laurie Gay, Shakti Ramkissoon, Jo-Anne Vergilio, Julia Elvin, Abdur Shakir, Jeffrey Ross, Philip Stephens, Vincent Miller, Siraj Ali
Journal: Journal of Thoracic Oncology (2017)
P2.06-008 Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
Authors: Missak Haigentz, John Nemunaitis, Melissa Johnson, Nisha Mohindra, Keith Eaton, Manish Patel, Mark Awad, Demiana Faltaos, Isan Chen, James Christensen, Diane Potvin, Tavette Neskorik, Matteo Levisetti, Edward Garon
Journal: Journal of Thoracic Oncology (2017)
P3.04-019 Nodal Upstaging in cN0 Lung Cancer is More Influenced by Tumor Size Than the Surgical Approach
Authors: Gregor Laimer, Caecilia Ng, Florian Kocher, Magdalena Sacher, Herbert Maier, Paolo Lucciarini, Thomas Schmid, Florian Augustin
Journal: Journal of Thoracic Oncology (2017)
Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia
Authors: Laurence Legros, Nathalie Ebran, Jean-Michel Karsenti, Faezeh Legrand, Lionel Mannone, Nicolas Mounier, Henri Vinti, Jill-Patrice Cassuto, Pierre-Simon Rohrlich, Anne-Odile Hueber
Journal: Blood (2012)
Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT.
Authors: Chiara Bonini, Fabio Ciceri, Maria Teresa Lupo Stanghellini, Attilio Bondanza, Zulma Magnani, Serena Kimi Perna, Massimo Bernardi, Jacopo Peccatori, Paolo Servida, Fulvio Crippa, Shin Kaneko, Veronica Valtolina, Monica Salomoni, Lucia Turchetto, Salvatore Toma, Catia Traversari, Paolo Bruzzi, Luca Castagna, Armando Santoro, Jane Apperley, Shimon Slavin, Scialini Colombi, Corrado Gallo Stampino, Marco Bregni, Claudio Bordignon
Journal: Blood (2006)
P1.03-031 Gynecological Malignancies and Imaging Patterns. An Interesting Case Report and Literature Surveillance
Authors: Nektarios Alevizopoulos, Vasiliki Ntalapera, Areti Dimitriadou, Anna Skoula, Theodoros Vagdatlis, Kiriaki Pissaki, Nickie Loukas, Michael Vaslamatzis
Journal: Journal of Thoracic Oncology (2017)
P2.03b-009 Brain Metastasis and Epidermal Growth Factor Receptor Mutations in Croatian Caucasians with Lung Adenocarcinoma
Authors: Katherina Sreter, Suzana Kukulj, Silvana Smojver-Jezek, Ante Rebic, Marina Serdarevic, Gordana Drpa, Filip Popovic, Bernard Budimir, Sven Seiwerth, Marko Jakopovic, Miroslav Samarzija
Journal: Journal of Thoracic Oncology (2017)
P275 Patient understanding, expectations and experiences of an interstitial lung disease specialist centre
Authors: M Lee, M Bennett, C Leonard, N Chadhuri
Journal: Thorax (2016)

<h3>Introduction</h3> Interstitial lung disease is the collective term used for a group of scarring lung conditions associated with debilitating symptoms, reduced life expectancy and a poor quality of life. NHS England commissioned ILD specialist centres to help co-ordinate patient care, arrive at accurate diagnoses faster and monitor the use of newly licensed anti-fibrotic medication. This qualitative study evaluates if specialist services significantly improves patient understanding and experiences of their disease. <h3>Method</h3> A two-part questionnaire was handed to new patients at an ILD specialist centre, part one assessed patient perspective before their appointment and part two after. Before and after results were compared against one another using a paired t-test. Total of 46 sets of data collected. <h3>Results</h3> Patients felt they were given more information about their diagnosis (mean 5.15 – &gt;9.08, p value &lt; 0.0001), prognosis (mean 4.76 – &gt;9.04, p value &lt; 0.0001) and treatment options (mean 4.63 – &gt;9.28, p value &lt; 0.0001). Patients felt they had more control over their disease (mean 3.67 – &gt;6.66, p value &lt; 0.001) and more confidence they were being managed correctly (mean 4.39 – &gt;8.52, p value &lt; 0.001). Patients felt more satisfied with their care after being seen at an ILD specialist clinic (mean 6.04 – &gt;9.44, p value &lt; 0.0001). More patients strongly agreed information given met their expectations (7/45 – &gt;37/46) and was delivered in a way that was clear and easy to understand (11/45 – &gt;36/45). 87% (40/46) of patients strongly agreed there is more benefit in being seen at a specialist centre. <h3>Conclusion</h3> Evidence supports the utilisation of specialist centres to manage patients with ILD. Results show there is a significant improvement in patient understanding, experiences and satisfaction.
P134 Methacholine challenge to demonstrate therapeutic equivalence of terbutaline via different turbuhaler devices in patients with mild to moderate asthma: appraisal of a phase iii, four-way crossover design
Authors: L Bjermer, G Gauvreau, D Postma, P O’Byrne, M van den Berge, L-P Boulet, O Beckman, T Persson, J Roman, M Carlholm, K-M Schutzer, G Eckerwall
Journal: Thorax (2016)

<h3>Background/objective</h3> To demonstrate therapeutic equivalence of terbutaline via two different Turbuhaler® devices by evaluating its protective effect against methacholine-induced bronchoconstriction in patients with stable asthma. <h3>Methods</h3> In this double-blind, double-dummy, multicentre, single-dose, 4-way crossover study, patients with stable, mild-to-moderate asthma (FEV1 ≥ 80% predicted normal) were randomised to 0.5 or 1.5 mg terbutaline via either Turbuhaler® M3 or M2 followed by a methacholine challenge test. Primary outcome variable: concentration of methacholine causing a 20% drop in FEV1 (PC20). Patients had to have a PC20 methacholine &lt; 8 mg/mL, reproducible after 2 weeks, and a stable baseline FEV1 at all visits (90–110% of enrolment value). <h3>Results</h3> 60 patients were randomised to treatment and completed the study. There was a clear dose–response for both devices. The within-device ratios (1.5 mg: 0.5 mg) were 1.79 and 1.87 for Turbuhaler M3 and M2, respectively (both p &lt; 0.001). The between-devices ratio (M3:M2) was 0.92 (95% CI: 0.75–1.13) for 0.5mg and 0.88 (95% CI 0.72–1.08) for 1.5 mg. Both CIs lie inside the interval (0.67–1.50), which was the pre-specified condition for equivalent effect. <h3>Conclusions</h3> Bronchoprotection with PC20 as the outcome measure in a standardised methacholine challenge model proved to be a useful design to show therapeutic equivalence between devices in patients with mild to moderate asthma. This model provides robust reproducible data, involves smaller patient numbers with fewer dropouts resulting in reduced costs versus a conventional efficacy study.
P3.03-025 Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma
Authors: Muhammad Alamgeer, Adrian Pick, Shakher Ramdave, Prashant Joshi, Beena Kumar, Vinod Ganju, Zdenka Prodanovic, Neil Watkins
Journal: Journal of Thoracic Oncology (2017)
The role of early life nutrition in the establishment of gastrointestinal microbial composition and function
Authors: Erin C. Davis, Mei Wang, Sharon M. Donovan
Journal: Gut Microbes (2017)

The development of the human infant intestinal microbiota is a sequential process that begins in utero and continues during the first 2 to 3 years of life. Microbial composition and diversity are shaped by host genetics and multiple environmental factors, of which diet is a principal contributor. An understanding of this process is of clinical importance as the microbiota acquired in early life influence gastrointestinal, immune and neural development, and reduced microbial diversity or dysbiosis during infancy is associated with disorders in infancy and later childhood. The goal of this article was to review the published literature that used culture-independent methods to describe the development of the gastrointestinal microbiota in breast- and formula-fed human infants as well as the impact of prebiotic and probiotic addition to infant formula, and the addition of solid foods.
Comparison of perioperative MAGIC chemotherapy versus neoadjuvant chemoradiotherapy in the treatment of localized distal esophagus and GE junction adenocarinoma in British Columbia.
Authors: D. Schellenberg, H. R. Kim, W. Y. Cheung, H. J. Lim
Journal: Journal of Clinical Oncology (2011)

e14509 Background: Perioperative chemotherapy and neoadjuvant chemoradiotherapy treatment modalities are frequently used for resectable gastroesophageal adenocarcinoma. However, little data exist in the literature to support one strategy over the other. A retrospective review was conducted to compare the outcomes of these 2 strategies in British Columbia, Canada. Methods: Patients with resectable distal esophagus and gastro-esophageal junction (GEJ) adenocarcinomas were identified using a provincial pharmacy database as having received 5FU, epirubicin and cisplatin (MAGIC) perioperatively or 5FU/cisplatin concurrent with radiation therapy (cXRT) preoperatively and followed by definitive surgery. A retrospective chart review was performed and data were abstracted. Survival was calculated using Kaplan Meier estimates and Chi-squared test was used to compare patient variables. Results: 48 patients were identified as undergoing perioperative treatment (24 patients in the MAGIC group and 24 patient received cXRT) and proceeding with surgical resection. Median age was 67 years in cXRT and 64 years in MAGIC (p=0.39). There were more patients with distal esophagus than GEJ tumors in the cXRT group when compared to the MAGIC group (79% vs. 33%, p<0.05). The cXRT group had more patients with an ECOG >2 (50% vs. 8%, p<0.05) and more patients with a dysphagia score > 2 (67% v.s 33%, p=0.02). Pathological complete response (pCR) rate was 42% for cXRT vs. 4% for MAGIC. 9 and 6 patients in the cXRT and MAGIC group relapsed; the median time to relapse was similar (12.4 mos for cXRT vs. 12.3 mos for MAGIC). Median follow-up for the surviving patients was 18.4 months. Median survival has not been reached, but the mean survival of MAGIC was 27.5 months and cXRT was 28.4 months (p=0.26). Conclusions: Survival is similar between the two treatment groups despite the cXRT group having more symptoms and lower ECOG. cXRT resulted in greater pCR. Based on this review, either treatment is reasonable and patient symptoms may guide this process.
P1.08-054 Uniportal VATS Lobectomy in the Treatment of NSCLC
Authors: Nenad Ilic, Josko Juricic, Dragan Krnic, Duje Orsulic, Ivan Simundza, Marijan Urlic, Nives Frleta Ilic, Darko Ilic
Journal: Journal of Thoracic Oncology (2017)
P1.06-012 Central and Peripheral Lung Adenocarcinomas Exhibit Different Timing and Predilection for Distant Metastasis
Authors: Thomas Klikovits, Zoltan Lohinai, Katalin Fabian, Márton Gyulai, Andrea Fodor, Judit Varga, Erika Baranya, Orsolya Pipek, István Csabai, Zoltan Szallasi, József Tímár, Balazs Hegedus, Balazs Dome, Judit Moldvay
Journal: Journal of Thoracic Oncology (2017)
S64 Rates and sites of recurrence following radical treatment of stage I lung cancer
Authors: MPT Kennedy, KL Lummis, K Spencer, K Franks, M Snee, MEJ Callister
Journal: Thorax (2016)

<h3>Introduction</h3> Lobectomy is the treatment of choice for medically operable patients with stage I lung cancer, with the best reported overall survival and lowest recurrence rates. Patient selection influences outcomes as demonstrated by wide variations in outcomes and reported recurrence rates for all radical lung cancer treatments. Some studies report recurrence rates following Stereotactic Ablative Radiotherapy (SABR) that are comparable to lobectomy. We aim to analyse the rates and site of recurrence in our patients who were radically treated for stage I lung cancer. <h3>Methods</h3> All patients with two years follow-up after radical treatment for stage I lung cancer (2008–2013) were included. Retrospective review of electronic patient records to identify outcomes, including the presence and site of any recurrence. <h3>Results</h3> 425 patients were identified. Treatment modalities included lobectomy 187 (44.0%), SABR 99 (23.3%), sub-lobar resection 85 (20.0%) and radical radiotherapy 54 (12.7%). There was pathological confirmation in 56.6% of SABR and 63.0% of radical radiotherapy. Patients treated with surgical resection were younger (mean age 69.0 vs 75.9 years, p &lt; 0.001) and had a better performance status (PS0–1 83.5% vs 37.9%, p &lt; 0.001), although larger tumours (T2a 53.4% vs 31.3%, p = 0.001). Mortality without cancer recurrence at two years was lower following surgery than non-surgical treatment (10.7% lobectomy and 11.8% sub-lobar resection vs 27.3% SABR and 25.9% radical radiotherapy, p &lt; 0.001). Overall recurrence rates at two years were 12.3% lobectomy, 11.8% sub-lobar resection, 17.2% SABR and 29.6% radical radiotherapy – differences not significant on uni-variable regression, which may relate to small patient numbers. Figure 1 demonstrates the sites of recurrence. Considering only those with pathological confirmation of cancer, recurrence rates at two years were 17.9% for SABR and 32.4% for radical radiotherapy. <h3>Conclusions</h3> The lowest recurrence rate was observed following surgical resection. In comparison, recurrence following SABR was non-significantly higher due to more loco-regional recurrence. Radical radiotherapy is associated with higher rates of overall, loco-regional and distant recurrence. Nodal recurrence was comparable between lobectomy, SABR and radical radiotherapy. This data is limited by low numbers as well as the confounding effects of early non-cancer deaths and incomplete pathological confirmation in the non-surgical treatment cohorts.
Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.
Authors: Makoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, Paola Neli, Kenji Ishitsuka, Masaharu Akiyama, Toshiaki Hayashi, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Constantine Mitsiades, Klaus Podar, Deepak Gupta, Donald H. Picker, Gary S. Jacob, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2004)
P3.03-042 Study Comparing Volume and TNM in Predicting Clinical Outcome in Malignant Pleural Mesothelioma
Authors: Claudia Proto, Diego Signorelli, Sandra Mallone, Francesca Greco, Giuseppina Calareso, Laura Botta, Giuseppe Lo Russo, Marina Garassino, Milena Vitali, Monica Ganzinelli, Nicoletta Zilembo, Marco Platania, Ugo Pastorino, Annalisa Trama
Journal: Journal of Thoracic Oncology (2017)